Latest Articles
GSK's Jemperli receives positive CHMP opinion for endometrial cancer - Investing.com
GSK's Jemperli receives positive CHMP opinion for endometrial cancer Investing.com
Published: Dec. 16, 2024, 5:30 p.m.
Different surgical methods of hysterectomy for the management of endometrial cancer: A systematic review and network meta-analysis - Frontiers
Different surgical methods of hysterectomy for the management of endometrial cancer: A systematic review and network meta-analysis Frontiers
Published: Dec. 16, 2024, 4:23 p.m.
Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer - OncLive
Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer OncLive
Published: Dec. 16, 2024, 4:21 p.m.
GSK’s Jemperli Set for Expanded EMA Approval for Endometrial Cancer - TipRanks
GSK’s Jemperli Set for Expanded EMA Approval for Endometrial Cancer TipRanks
Published: Dec. 16, 2024, 7:45 a.m.
EU recommends expanding use of GSK endometrial cancer drug - ShareCast
EU recommends expanding use of GSK endometrial cancer drug ShareCast
Published: Dec. 16, 2024, 7:35 a.m.
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis Seeking Alpha
Published: Dec. 12, 2024, 8:25 p.m.
Integrating Psychosocial Support and Quality of Life into Endometrial Cancer Pathways - Journal of Clinical Pathways
Integrating Psychosocial Support and Quality of Life into Endometrial Cancer Pathways Journal of Clinical Pathways
Published: Dec. 12, 2024, 4:25 p.m.
Endometrial Cancer Market Diagnosing and Treating a Growing - openPR
Endometrial Cancer Market Diagnosing and Treating a Growing openPR
Published: Dec. 11, 2024, 10:11 a.m.
Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors - Frontiers
Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors Frontiers
Published: Dec. 10, 2024, 4:36 p.m.
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - BioSpace
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer BioSpace
Published: Dec. 10, 2024, 12:23 p.m.
Link copied to clipboard!